07:00 , Jul 25, 2011 |  BC Week In Review  |  Clinical News

ATH012: Phase IIa started

Advancell and Neurotec began the European Phase IIa NeuroAdvan trial to evaluate oral NT-KO-003 in 105 patients. The companies, which are co-developing the product, plan to out-license it after completing the trial. Advancell Advanced In...